Table 3.
Correlation between CSF and blood NfL levels.
| Diagnosis | Correlation strength | Blood NfL levels (pg/mL, range/IQR/±SD) | Fluid | Platform | CSF NfL levels (pg/mL, range/IQR/±SD) | Platform | Ref. |
|---|---|---|---|---|---|---|---|
| HC |
r: 0.350, P: 0.014 r: 0.574, P: 0.008 r: 0.59, P: 0.004 r: 0.772, P < 0.0001 r: 0.39, P: 0.029 |
‐ 22.0, (12.0 ‐ 36.5) 11, (8 ‐ 14) ‐, (2.8 ‐ 53.8) 11.5 (± 6.5) |
Serum Serum Serum Serum Serum |
Simoa HD‐1* ECL Simoa HD‐1 Simoa HD‐1 Simoa HD‐1 |
‐ 466.5, (338.7 ‐ 651.7) 212, (151 ‐ 289) ‐ 1.265 (±551) |
Simoa HD‐1* ECL ELISA Simoa HD‐1 NA |
[15] [47] [44] [27] [46] |
| AD |
r: 0.612, P < 0.0001 r: 0.580, P < 0.001 r: 0.568, P < 0.001 r:0.666, P = 0.003 |
‐ ‐, (31.0‐44.1) 46.8, (32.7‐70.7) 38.1, ‐ |
Serum Plasma Plasma Serum |
Simoa HD‐1 Simoa HD‐1 Simoa HD‐1 Simoa HD‐1 |
‐ ‐, 1070‐2778 608.3 (429.1, 817.7) 1595, ‐ |
Simoa HD‐1 ELISA ELISA ELISA |
[15] [88] [93] [134] |
| ALS |
r: 0.781, P < 0.001 r: 0.79, P < 0.0001 |
90, (54.5 ‐ 151.0) 179, ‐ |
Serum Serum |
ECL ECL |
7304, (4376 ‐ 11736) ‐ |
ECL ELISA |
[47] [48] |
| FTD | r: 0.706, P < 0.0001 | 56.9, ‐ | Serum | Simoa HD‐1 | 2948, ‐ | ELISA | [134] |
| HAD | r: 0.89, P < 0.0001 | 114 (46.0 ‐ 235) | Plasma | Simoa HD‐1 | 16185 (1513 ‐ 43010) | ELISA | [13] |
| HD | r:0.868, P < 0.0001 | 31.7 (24.9 ‐ 50.6) | Plasma | Simoa HD‐1 | 1871, (1312 ‐ 2461) | ELISA | [139] |
| MS |
r: 0.77, P < 0.001 r: 0.79, P < 0.0001 r: 0.72, P < 0.0001 r: 0.63, P < 0.001 |
35.9, (22.1 ‐ 61.7) 16.4 (±14.4) 25.0 (±43.9) 17, (12 ‐ 22) |
Serum Plasma Serum Serum |
Simoa HD‐1* Simoa HD‐1 Simoa HD‐1 Simoa HD‐1 |
1521, (814 ‐ 2888) 2368 (±1947) 2368 (±1947) 895, (300 ‐ 2060) |
Simoa HD‐1* Simoa HD‐1 Simoa HD‐1 ELISA |
[32] [26] [26] [44] |
| PD |
r: 0.589, P < 0.001 r: 0.34, P:0.012 |
9, (4 ‐ 19)** 10.4, (±4.9) |
Plasma Serum |
Simoa HD‐1 Simoa HD‐1 |
896, ‐ 1.249, (±666) |
ELISA NA |
[45] [46] |
| TBI ‐ Boxers | r: 0.86, P: 0.0003 | 30, (20‐70)** | Serum | Simoa HD‐1 | 845, ‐ | ELISA | 20 |
AD: Alzheimer’s Disease; ALS: amyotrophic lateral sclerosis; FTD: frontotemporal dementia; HAD: HIV‐associated dementia; HD: Huntington disease; IQR: Interquartile range; MS: multiple sclerosis; ‐: not available; PD: Parkinson’s disease; TBI: traumatic brain injury.
Basel protocol, the concentrations in blood are ~ 2 fold higher compared to the commercial Simoa NfL kit.
Concentrations derived from Figure.